Curated News
By: NewsRamp Editorial Staff
April 03, 2026
TibaRay Opens FLASH Radiotherapy Investment to Public via Wefunder Campaign
TLDR
- TibaRay's Wefunder campaign offers early investment in FLASH radiotherapy technology that could revolutionize cancer treatment and provide significant market advantage.
- TibaRay is developing Galactica linear accelerator technology using $27 million in funding and 20+ patents to enable ultrafast radiation delivery for FLASH radiotherapy.
- TibaRay's FLASH radiotherapy technology aims to reduce damage to healthy tissue during cancer treatment, potentially improving patient outcomes and quality of life.
- TibaRay's Stanford-spinout technology delivers radiation hundreds of times faster than current systems, with its accelerator already integrated into Leo Cancer Care's upright system.
Impact - Why it Matters
This development represents a significant advancement in cancer treatment technology that could fundamentally change radiation therapy. FLASH radiotherapy's potential to reduce damage to healthy tissue while maintaining tumor control addresses one of radiation oncology's biggest challenges—minimizing side effects. For cancer patients, this could mean shorter treatment times, fewer complications, and potentially better outcomes. The public investment opportunity through Wefunder democratizes access to cutting-edge medical technology development, allowing individuals to support innovations that could save lives. As cancer remains a leading cause of death worldwide, advancements like TibaRay's technology could impact millions of patients and transform standard treatment protocols across oncology centers globally.
Summary
TibaRay, a Stanford spinout company, has launched a Regulation CF crowdfunding campaign on Wefunder, opening investment opportunities to individual investors as it advances its groundbreaking accelerator technology for FLASH radiotherapy. The company aims to revolutionize cancer treatment by developing next-generation systems that deliver radiation hundreds of times faster than current methods, potentially reducing damage to healthy tissue while maintaining tumor control. This campaign marks a significant milestone in making cutting-edge medical technology accessible to public investors through the Wefunder platform.
Built on decades of accelerator physics and medical physics research, TibaRay has already secured over $27 million in development funding, including more than $14 million in non-dilutive federal research grants. The company boasts an impressive intellectual property portfolio with over 20 issued and pending patents related to next-generation radiotherapy systems. TibaRay's proprietary Galactica linear accelerator has already achieved its first commercial integration with Leo Cancer Care's upright radiotherapy system, demonstrating real-world application of their technology. Investors can explore the full opportunity, including detailed technology specifications, strategic partnerships, and comprehensive development plans on the TibaRay campaign page.
The company follows a phased commercialization strategy, initially generating revenue by deploying its accelerator technology across medical and adjacent markets including imaging, security scanning, and non-destructive testing. Their long-term objective focuses on deploying the PHASER radiotherapy system specifically designed to enable ultrafast treatment delivery. This strategic approach allows TibaRay to build revenue streams while advancing toward their ultimate goal of transforming cancer treatment. The original release can be viewed on www.newmediawire.com, providing additional context about this innovative medical technology company's journey toward making FLASH radiotherapy a clinical reality.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, TibaRay Opens FLASH Radiotherapy Investment to Public via Wefunder Campaign
